Developer docs
API playgroundTry for free, no card

Search company profiles

Crystal Pharmatech

Full company profile

uuid0047tsl

Namestring
Crystal Pharmatech
Legal namestring
Crystal Pharmatech Co., Ltd.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Crystal Pharmatech is a privately held, China-incorporated global CRO and CDMO founded in 2010 that specializes in solid-state research and advanced formulation development for small molecule drugs. The company serves pharmaceutical and biotechnology companies across the development lifecycle — from early developability assessment through API form selection, crystallization development, pre-formulation, formulation development, GMP clinical and commercial manufacturing, and clinical supply — under its proprietary Mol2Med™ First-Time-Right 3-STEP methodology. It has expanded into adjacent modalities via the Crystal Bio Solutions division (biologics characterization, bioanalytical services, quantitative clinical pharmacology) and the Crystal NAX division (DNA/RNA synthesis, LNP formulation, and early-phase manufacturing for nucleic acid therapeutics). Core technology differentiators include the MicroED platform (first dedicated deployment in Asia-Pacific via partnership with ELDICO Scientific), an OEB4/OEB5 high-potency laboratory, spray drying and hot-melt extrusion capabilities for amorphous solid dispersions, pediatric mini-tablet technology, and the Molecule-Material-Medicine formulation strategy.

The company operates four R&D centers spanning Cranbury (New Jersey, two sites), Pleasanton (California), Mississauga (Toronto, Canada), and Suzhou (China headquarters and GMP manufacturing in Biobay), with a combined R&D and GMP footprint of 519,090 ft² and approximately 300 employees globally. Revenue is generated through project-based CRO and CDMO contracts — including managed services for GMP manufacturing — with multi-year contract cadences and quote-based pricing tied to project scope and complexity. Distribution is direct via business development teams in the US, Canada, and China; the company does not use third-party resellers.

Crystal Pharmatech has served over 2,000 clients and completed over 4,000 projects, including work for 8 of the 10 largest multinational pharmaceutical companies, with a track record of 100+ New Chemical Entities delivered and 15 commercial drug products supported. Its customer base spans large multinational pharma, mid-sized pharma, biotechs, virtual pharma, startups, and non-profit organizations. Multi-jurisdiction regulatory credentials — GMP/GDP certification by SGS, EU QP audit pass, China Drug Product Manufacturing License, CNAS reaccreditation, and US client remote audit pass — enable cross-border clinical and commercial supply.

Short descriptiontext

Crystal Pharmatech is a global CRO/CDMO founded in 2010, providing solid-state research, formulation development, and GMP manufacturing services for small molecule, biologic, and nucleic acid therapeutics to pharmaceutical and biotechnology companies across the US, Canada, and China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCranbury, New Jersey, United States
HQ citystring
Cranbury, New Jersey
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research organization, solid-state characterization, formulation development services, pharmaceutical CDMO services, drug development research
Industry5 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Research and Manufacturing (CRO/CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CRO Services
TypeProfessional Services
Description

Contract research organization services including solid-state research, polymorph/salt/co-crystal screening, crystallization development, pre-formulation studies, and analytical services. Revenue is generated through project-based contracts with pharmaceutical and biotech companies.

crystalpharmatech.com
2CDMO Manufacturing Services
TypeManaged Services
Description

Contract development and manufacturing organization services including clinical and commercial manufacturing, GMP production, and clinical supply. Revenue generated through manufacturing service contracts with cGMP facilities.

crystalpharmatech.com
3Biologics and Nucleic Acid Services
TypeProfessional Services
Description

Through Crystal Bio Solutions and Crystal NAX divisions, providing biologics characterization, bioanalytical services, quantitative clinical pharmacology, DNA/RNA synthesis, and LNP formulation services

crystalpharmatech.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Project-based CRO/CDMO services with custom pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing determined through quotation process based on project requirements, complexity, timeline, and scope of services required

crystalpharmatech.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Crystal Bio Solutions
Description

Biologics characterization, CMC analytics, bioanalytical and biomarker services, and quantitative clinical pharmacology.

crystalpharmatech.com
+3 more records
Core offering1 text field

Crystal Pharmatech operates as a contract research and contract development organization (CRO/CDMO) providing solid-state research, preformulation, formulation development, and GMP manufacturing services for small molecule pharmaceutical compounds. The company supports drug developers across solid form selection, crystallization process development, and finished dosage form manufacturing using proprietary platforms such as Mol2Med and a MicroED-based single crystal structure analysis platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Solid form screening and crystallization of over 2,000 drug molecules over 12 years
+3 more records
Product overview1 text field

Crystal Pharmatech operates as a global contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering an integrated portfolio of pharmaceutical development services. The company's core offering is the proprietary Mol2Med™ First-Time-Right 3-STEP Approach, a unified methodology that guides clients from early molecule evaluation through clinical manufacturing. The service portfolio spans three main divisions: Small Molecule services (including developability assessment, API form and solid-state research, crystallization development, pre-formulation studies, analytical research, formulation development, and GMP clinical/commercial manufacturing), Crystal Bio Solutions (biologics characterization, bioanalytical services, and quantitative clinical pharmacology), and Crystal NAX (DNA/RNA synthesis, LNP formulation, and early-phase manufacturing for nucleic acid therapeutics). Supporting these are technology platforms for oral dosage forms, including conventional formulations, enabling/bioavailability enhancement technologies for insoluble drugs and PROTACs, and pediatric mini-tablet formulations. The company has also developed advanced capabilities including a dedicated MicroED platform for absolute structure determination and an OEB4/OEB5 high-potency laboratory for handling highly potent compounds.

Product and service1 record
1Solid-State Research and Solid Form Selection Services
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-01
Description

Crystal Pharmatech became the first company in Asia-Pacific to deploy a dedicated MicroED platform through strategic collaboration with ELDICO Scientific. This partnership enables advanced absolute structure determination and crystal identification capabilities for sub-micron crystals, significantly enhancing their solid-state characterization services.

2Particle Sciences
Strategic tierCoreTypeStrategic or Co-development Partner
Description

US-China pharmaceutical CRO partnership formed to provide integrated cross-border services combining Particle Sciences' formulation expertise with Crystal Pharmatech's solid-state research capabilities.

crystalpharmatech.com
3Xceleron
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Partnership to improve early clinical development utilizing absolute bioavailability trials and solid-state solutions. Combines Xceleron's pharmacokinetic expertise with Crystal Pharmatech's solid-state characterization capabilities.

crystalpharmatech.com
4Divamics
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Strategic collaboration to accelerate drug development through AI, crystal form, and formulation innovation. Integrates Divamics' AI capabilities with Crystal Pharmatech's crystal form and formulation expertise.

crystalpharmatech.com
5CATUG
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

CATUG and Crystal Bio established strategic partnership launching the CATUG-Crystal Joint Lab dedicated to advanced nucleic acid analytical services, combining expertise in nucleic acid therapeutics development.

crystalpharmatech.com
Strategic tierRegulatoryTypeOthers
Description

Crystal Formulation Services successfully passed dual certification of GMP and GDP conducted by SGS, an international testing, inspection, and certification company. SGS provides regulatory auditing and certification services.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lonza is one of the world's largest CDMOs with API, formulation, and biologics manufacturing at global scale. Competes for the same large pharma outsourcing budgets and represents a major benchmark peer for capacity, capabilities, and regulatory footprint.

TypeBroad incumbent
Description

Catalent is a major global CDMO offering formulation, softgel, biologics, and clinical supply across hundreds of programs. Broad incumbent with overlapping capabilities but much larger scale and breadth than Crystal Pharmatech.

3Syngene International
TypeDirect peer
Description

Syngene is an India-headquartered integrated CRO/CDMO providing drug substance, formulation development, and GMP manufacturing — serving global pharma with similar scale, cost base, and scope to Crystal Pharmatech.

TypeDirect peer
Description

Pharmaron is a China-based integrated CRO/CDMO with formulation development, GMP manufacturing, and discovery services. Geographic and operational peer with broader scope than Crystal Pharmatech.

TypeDirect peer
Description

Sai Life Sciences is an India-based CRO/CDMO offering formulation development, analytical services, and GMP manufacturing for small molecules. It targets similar global pharma clients and competes in enabling formulation and CDMO services for poorly soluble compounds.

TypeBroad incumbent
Description

Patheon, integrated into Thermo Fisher's pharma services, is a top global CDMO with API, oral solid dose, sterile, and biologics capabilities. Represents the broader commercial CDMO peer set for Crystal Pharmatech's drug product CDMO offering.

TypeDirect peer
Description

Solvias is a Swiss-based CRO/CDMO with deep specialization in solid-state chemistry, polymorphism, salt/co-crystal screening, and formulation development for small molecules — directly comparable to Crystal Pharmatech's core Mol2Med workflow. It is one of the closest functional analogs in the solid-state CRO space.

TypeDirect peer
Description

Almac is a UK/Northern Ireland-headquartered CDMO with strong formulation development, pre-formulation, and GMP manufacturing services for small molecule drug products — overlaps closely with Crystal's formulation and clinical supply offering.

TypeBroad incumbent
Description

Eurofins operates a global Discovery/CRO business including solid-state characterization, formulation support, and analytical services. Broad incumbent with overlapping specialty CRO capabilities that compete for outsourced pharma R&D budgets.

TypeDirect peer
Description

WuXi STA is a leading China-based CDMO with integrated API development, solid-state research, formulation, and GMP manufacturing. Most direct geographic and operational peer to Crystal Pharmatech, with substantially larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Crystal Pharmatech

Pharmaceutical Contract Research and Manufacturing (CRO/CDMO)crystalpharmatech.com

Crystal Pharmatech is a global CRO/CDMO founded in 2010, providing solid-state research, formulation development, and GMP manufacturing services for small molecule, biologic, and nucleic acid therapeutics to pharmaceutical and biotechnology companies across the US, Canada, and China.

What Crystal Pharmatech does

Crystal Pharmatech is a privately held, China-incorporated global CRO and CDMO founded in 2010 that specializes in solid-state research and advanced formulation development for small molecule drugs. The company serves pharmaceutical and biotechnology companies across the development lifecycle — from early developability assessment through API form selection, crystallization development, pre-formulation, formulation development, GMP clinical and commercial manufacturing, and clinical supply — under its proprietary Mol2Med™ First-Time-Right 3-STEP methodology. It has expanded into adjacent modalities via the Crystal Bio Solutions division (biologics characterization, bioanalytical services, quantitative clinical pharmacology) and the Crystal NAX division (DNA/RNA synthesis, LNP formulation, and early-phase manufacturing for nucleic acid therapeutics). Core technology differentiators include the MicroED platform (first dedicated deployment in Asia-Pacific via partnership with ELDICO Scientific), an OEB4/OEB5 high-potency laboratory, spray drying and hot-melt extrusion capabilities for amorphous solid dispersions, pediatric mini-tablet technology, and the Molecule-Material-Medicine formulation strategy.

The company operates four R&D centers spanning Cranbury (New Jersey, two sites), Pleasanton (California), Mississauga (Toronto, Canada), and Suzhou (China headquarters and GMP manufacturing in Biobay), with a combined R&D and GMP footprint of 519,090 ft² and approximately 300 employees globally. Revenue is generated through project-based CRO and CDMO contracts — including managed services for GMP manufacturing — with multi-year contract cadences and quote-based pricing tied to project scope and complexity. Distribution is direct via business development teams in the US, Canada, and China; the company does not use third-party resellers.

Crystal Pharmatech has served over 2,000 clients and completed over 4,000 projects, including work for 8 of the 10 largest multinational pharmaceutical companies, with a track record of 100+ New Chemical Entities delivered and 15 commercial drug products supported. Its customer base spans large multinational pharma, mid-sized pharma, biotechs, virtual pharma, startups, and non-profit organizations. Multi-jurisdiction regulatory credentials — GMP/GDP certification by SGS, EU QP audit pass, China Drug Product Manufacturing License, CNAS reaccreditation, and US client remote audit pass — enable cross-border clinical and commercial supply.

Crystal Pharmatech firmographics

Firmographics
Name
Crystal Pharmatech
Legal name
Crystal Pharmatech Co., Ltd.
Website
https://crystalpharmatech.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Crystal Pharmatech is a global CRO/CDMO founded in 2010, providing solid-state research, formulation development, and GMP manufacturing services for small molecule, biologic, and nucleic acid therapeutics to pharmaceutical and biotechnology companies across the US, Canada, and China.
Ownership category
akta.pro rank

Crystal Pharmatech industry classification

Industry
Product category
Pharmaceutical Contract Research and Manufacturing (CRO/CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Contract research organization
  • Solid-state characterization
  • Formulation development services
  • Pharmaceutical CDMO services
  • Drug development research

Where Crystal Pharmatech is headquartered

Location

Headquarters

HQ city
Cranbury, New Jersey
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Crystal Pharmatech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. CRO Services: Contract research organization services including solid-state research, polymorph/salt/co-crystal screening, crystallization development, pre-formulation studies, and analytical services. Revenue is generated through project-based contracts with pharmaceutical and biotech companies.
  2. CDMO Manufacturing Services: Contract development and manufacturing organization services including clinical and commercial manufacturing, GMP production, and clinical supply. Revenue generated through manufacturing service contracts with cGMP facilities.
  3. Biologics and Nucleic Acid Services: Through Crystal Bio Solutions and Crystal NAX divisions, providing biologics characterization, bioanalytical services, quantitative clinical pharmacology, DNA/RNA synthesis, and LNP formulation services

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based CRO/CDMO services with custom pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Crystal Pharmatech product offering

Product offering

Core offering

Crystal Pharmatech operates as a contract research and contract development organization (CRO/CDMO) providing solid-state research, preformulation, formulation development, and GMP manufacturing services for small molecule pharmaceutical compounds. The company supports drug developers across solid form selection, crystallization process development, and finished dosage form manufacturing using proprietary platforms such as Mol2Med and a MicroED-based single crystal structure analysis platform.

Product overview

Crystal Pharmatech operates as a global contract research organization (CRO) and contract development and manufacturing organization (CDMO) offering an integrated portfolio of pharmaceutical development services. The company's core offering is the proprietary Mol2Med™ First-Time-Right 3-STEP Approach, a unified methodology that guides clients from early molecule evaluation through clinical manufacturing. The service portfolio spans three main divisions: Small Molecule services (including developability assessment, API form and solid-state research, crystallization development, pre-formulation studies, analytical research, formulation development, and GMP clinical/commercial manufacturing), Crystal Bio Solutions (biologics characterization, bioanalytical services, and quantitative clinical pharmacology), and Crystal NAX (DNA/RNA synthesis, LNP formulation, and early-phase manufacturing for nucleic acid therapeutics). Supporting these are technology platforms for oral dosage forms, including conventional formulations, enabling/bioavailability enhancement technologies for insoluble drugs and PROTACs, and pediatric mini-tablet formulations. The company has also developed advanced capabilities including a dedicated MicroED platform for absolute structure determination and an OEB4/OEB5 high-potency laboratory for handling highly potent compounds.

Differentiator

Problem solved

Functional benefit

Brands

  • Crystal Bio Solutions: Biologics characterization, CMC analytics, bioanalytical and biomarker services, and quantitative clinical pharmacology.
  • Crystal NAX
  • Crystal Formulation Services
  • Mol2Med™

Products and services

  • Solid-State Research and Solid Form Selection Services

Quantifiable outcome

  • Solid form screening and crystallization of over 2,000 drug molecules over 12 years
  • +3 more outcomes

Companies that use Crystal Pharmatech

Customer profile

Named customers11 records

Segments3 records

Ideal customer profiles1 record

Crystal Pharmatech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Crystal Pharmatech partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, strategic and regulatory.

  • ELDICO ScientificcoreTechnology or Integration · 1 April 2026Crystal Pharmatech became the first company in Asia-Pacific to deploy a dedicated MicroED platform through strategic collaboration with ELDICO Scientific. This partnership enables advanced absolute structure determination and crystal identification capabilities for sub-micron crystals, significantly enhancing their solid-state characterization services.
  • Particle SciencescoreStrategic or Co-development PartnerUS-China pharmaceutical CRO partnership formed to provide integrated cross-border services combining Particle Sciences' formulation expertise with Crystal Pharmatech's solid-state research capabilities.
  • XceleronstrategicStrategic or Co-development PartnerPartnership to improve early clinical development utilizing absolute bioavailability trials and solid-state solutions. Combines Xceleron's pharmacokinetic expertise with Crystal Pharmatech's solid-state characterization capabilities.
  • DivamicsstrategicStrategic or Co-development PartnerStrategic collaboration to accelerate drug development through AI, crystal form, and formulation innovation. Integrates Divamics' AI capabilities with Crystal Pharmatech's crystal form and formulation expertise.
  • CATUGstrategicStrategic or Co-development PartnerCATUG and Crystal Bio established strategic partnership launching the CATUG-Crystal Joint Lab dedicated to advanced nucleic acid analytical services, combining expertise in nucleic acid therapeutics development.
  • SGSregulatoryOthersCrystal Formulation Services successfully passed dual certification of GMP and GDP conducted by SGS, an international testing, inspection, and certification company. SGS provides regulatory auditing and certification services.

Scale indicators12 records

Recent moves10 records

Expansion highlights7 records

Crystal Pharmatech competitors and assessment

Company assessment

Broad incumbents

  • Lonza: Lonza is one of the world's largest CDMOs with API, formulation, and biologics manufacturing at global scale. Competes for the same large pharma outsourcing budgets and represents a major benchmark peer for capacity, capabilities, and regulatory footprint.
  • Catalent: Catalent is a major global CDMO offering formulation, softgel, biologics, and clinical supply across hundreds of programs. Broad incumbent with overlapping capabilities but much larger scale and breadth than Crystal Pharmatech.
  • Patheon (Thermo Fisher Scientific): Patheon, integrated into Thermo Fisher's pharma services, is a top global CDMO with API, oral solid dose, sterile, and biologics capabilities. Represents the broader commercial CDMO peer set for Crystal Pharmatech's drug product CDMO offering.
  • Eurofins Scientific: Eurofins operates a global Discovery/CRO business including solid-state characterization, formulation support, and analytical services. Broad incumbent with overlapping specialty CRO capabilities that compete for outsourced pharma R&D budgets.

Direct peers

  • Syngene International: Syngene is an India-headquartered integrated CRO/CDMO providing drug substance, formulation development, and GMP manufacturing — serving global pharma with similar scale, cost base, and scope to Crystal Pharmatech.
  • Pharmaron: Pharmaron is a China-based integrated CRO/CDMO with formulation development, GMP manufacturing, and discovery services. Geographic and operational peer with broader scope than Crystal Pharmatech.
  • Sai Life Sciences: Sai Life Sciences is an India-based CRO/CDMO offering formulation development, analytical services, and GMP manufacturing for small molecules. It targets similar global pharma clients and competes in enabling formulation and CDMO services for poorly soluble compounds.
  • Solvias: Solvias is a Swiss-based CRO/CDMO with deep specialization in solid-state chemistry, polymorphism, salt/co-crystal screening, and formulation development for small molecules — directly comparable to Crystal Pharmatech's core Mol2Med workflow. It is one of the closest functional analogs in the solid-state CRO space.
  • Almac Group: Almac is a UK/Northern Ireland-headquartered CDMO with strong formulation development, pre-formulation, and GMP manufacturing services for small molecule drug products — overlaps closely with Crystal's formulation and clinical supply offering.
  • WuXi AppTec (WuXi STA): WuXi STA is a leading China-based CDMO with integrated API development, solid-state research, formulation, and GMP manufacturing. Most direct geographic and operational peer to Crystal Pharmatech, with substantially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Crystal Pharmatech social profiles

Digital presence

Crystal Pharmatech compliance and trust

Trust signal

Compliance6 records

Crystal Pharmatech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Crystal Pharmatech leadership team

Management profile

Number of profiles

Profiles1 record

Crystal Pharmatech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Crystal Pharmatech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Crystal Pharmatech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crystal Pharmatech

What does Crystal Pharmatech do?

Crystal Pharmatech operates as a contract research and contract development organization (CRO/CDMO) providing solid-state research, preformulation, formulation development, and GMP manufacturing services for small molecule pharmaceutical compounds. The company supports drug developers across solid form selection, crystallization process development, and finished dosage form manufacturing using proprietary platforms such as Mol2Med and a MicroED-based single crystal structure analysis platform.

Is Crystal Pharmatech a public or private company?

Crystal Pharmatech is a private company. It is classified as unknown and is currently operating.

When was Crystal Pharmatech founded?

Crystal Pharmatech was founded in 2010. It employs 51 to 100 people.

Where is Crystal Pharmatech based?

Crystal Pharmatech is headquartered in Cranbury, New Jersey, United States, in the North America region.

How does Crystal Pharmatech make money?

Three revenue lines are on record. CRO Services are the primary driver. The others are CDMO Manufacturing Services and biologics and Nucleic Acid Services.

Who are Crystal Pharmatech's main competitors?

Broad incumbents on record are Lonza, Catalent, Patheon (Thermo Fisher Scientific) and Eurofins Scientific. Direct peers are Syngene International, Pharmaron, Sai Life Sciences, Solvias, Almac Group and WuXi AppTec (WuXi STA).

Does Crystal Pharmatech have an API?

No public API is recorded for Crystal Pharmatech.

What industry is Crystal Pharmatech in?

Crystal Pharmatech's product category is Pharmaceutical Contract Research and Manufacturing (CRO/CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGAHAI, Solid-State Chemistry & Preformulation (Polymorph/Crystallization). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AZoMCrystal Pharmatech Completes ELDICO ED-1 Installation; Dedicated MicroED Now in Routine ServiceCrystal Pharmatech completed installation of the ELDICO ED-1 electron diffractometer at its Suzhou R&D center, the first in Asia-Pacific. MicroED services are now open to clients worldwide, with results in one to two weeks or expedited in 48 hours. The instrument is expected to become a workhorse for solid-state research.News-MedicalCrystal Pharmatech completes ELDICO ED-1 installation; Dedicated MicroED now in routine serviceCrystal Pharmatech completed installation of the ELDICO ED-1 electron diffractometer at its Suzhou R&D center, the first in Asia-Pacific. MicroED services on the ED-1 are now open to clients worldwide, with results in one to two weeks or expedited in 48 hours. The instrument is expected to become a workhorse for solid-state research.PR NewswireCrystal Pharmatech Completes ELDICO ED-1 Installation; Dedicated MicroED Now in Routine ServiceCrystal Pharmatech completed installation of the ELDICO ED-1 electron diffractometer at its Suzhou R&D center, the first in Asia-Pacific. MicroED services are now open to clients worldwide, with results in as little as 48 hours. The instrument is integrated into solid-form screening, enabling structure determination from sub-micron powders.PR Newswire APACCrystal Pharmatech Completes ELDICO ED-1 Installation; Dedicated MicroED Now in Routine ServiceCrystal Pharmatech completed installation of the ELDICO ED-1 electron diffractometer at its Suzhou R&D center, the first in Asia-Pacific. The instrument is now operational, with MicroED services open to clients worldwide, delivering results in one to two weeks or as little as 48 hours. The company will showcase the instrument at its Boston Symposium on November 19.PR NewswireCrystal Pharmatech Completes ELDICO ED-1 Installation; Dedicated MicroED Now in Routine ServiceCrystal Pharmatech completed installation of the ELDICO ED-1 electron diffractometer at its Suzhou R&D center, the first in Asia-Pacific. MicroED services are now open to clients worldwide, with results in as little as 48 hours. The instrument is integrated into solid-form screening, enabling structure determination from sub-micron powders.